Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Stemline Therapeutics Inc (NASDAQ:STML)

8.45
Delayed Data
As of May 26
 +0.10 / +1.20%
Today’s Change
5.50
Today|||52-Week Range
14.60
-21.03%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$212.2M

Company Description

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Contact Information

Stemline Therapeutics, Inc.
750 Lexington Avenue
New York New York 10022
P:(646) 502-2310
Investor Relations:

Employees

Shareholders

Mutual fund holders28.31%
Other institutional27.35%
Individual stakeholders11.94%

Top Executives

Ivan BergsteinChairman, President & Chief Executive Officer
Kenneth HobermanChief Operating Officer & Secretary
David G. GioncoPrincipal Financial Officer